<DOC>
	<DOCNO>NCT00565097</DOCNO>
	<brief_summary>To assess efficacy lanreotide control total liver volume patient polycystic liver study perform . A minimum 38 patient recruit randomized ( 1:1 ) receive either verum placebo . Lanreotide already use disease state find safe non-toxic .</brief_summary>
	<brief_title>Lanreotide Treatment Polycystic Livers</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Cysts</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Hepatomegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>18 yrsof age Multiple cysts &gt; 20 Cooperating patient Is willing able comply study drug regimen study requirement Willingness give write informed consent Use oral anticonceptives estrogen suppletion Females pregnant breastfeed History evidence chronic pulmonary disease associate functional limitation History severe cardiac disease History evidence severe illness condition would make patient , opinion investigator , unsuitable study Symptomatic gallstone Renal failure require hemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Polycystic Liver Disease</keyword>
	<keyword>Autosomal Dominant Polycystic Kidney Disease</keyword>
	<keyword>Liver cyst</keyword>
	<keyword>Lanreotide</keyword>
</DOC>